



## Program

**1<sup>st</sup> Cancer Crosslinks meeting**  
at Rikshospitalet in Oslo – January 15, 2009

| Session                | Topic                                                                                                                                                                                                                 | Presentations | Presenter                                                                                                            |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------------------------------------------------------------------------|
| 10:00 – 10:30 h        | <b>“Cancer Crosslinks”: Organizers and Objectives</b>                                                                                                                                                                 |               | Bjarte Reve, Oslo Cancer Cluster<br>Tove Flem Jacobsen, Clavis Pharma<br>Benedikte Thunes Akre, Bristol-Myers Squibb |
| 10:30 – 10:50 h        | <b>Opening Keynote:</b><br><b>“CML as model for disease evolution in human cancer”</b>                                                                                                                                |               | Tobias Gedde-Dahl,<br>Rikshospitalet, Oslo                                                                           |
| <b>10:50 – 12:35 h</b> | <b>Session 1: Biological Basis of Therapy</b><br><b>Chair (Hematologist): Anders Waage, St. Olavs Hospital, Trondheim</b><br><b>Chair (Scientist): Stefan Krauss, SFI CAST, Rikshospitalet, Oslo</b>                  |               |                                                                                                                      |
| 10:55 – 11:35 h        | <b>Cancer Stem Cells and their role in different malignancies</b>                                                                                                                                                     |               |                                                                                                                      |
|                        | “Cancer stem cells: Do they exist and can they be defined?<br>– From a scientific to a clinical perspective”                                                                                                          |               |                                                                                                                      |
|                        | The scientist:                                                                                                                                                                                                        |               | Rolf Bjerkvig,<br>Universitetet i Bergen                                                                             |
|                        | The clinician:                                                                                                                                                                                                        |               | Iver Langmoen,<br>Ullevål Universitetssykehus, Oslo                                                                  |
| 11:40 – 12:20 h        | <b>Handling the multifaceted essence of cancer – tumors and biomarkers</b>                                                                                                                                            |               |                                                                                                                      |
|                        | The scientist:                                                                                                                                                                                                        |               | Anne-Lise Børresen Dale,<br>Radiumhospitalet, Oslo                                                                   |
|                        | The clinician:                                                                                                                                                                                                        |               | Bjørn Naume,<br>Radiumhospitalet, Oslo                                                                               |
| 12:20 – 12:35 h        | <b>Discussion</b>                                                                                                                                                                                                     |               |                                                                                                                      |
| 12:35 – 13:15 h        | <b>LUNCH &amp; NETWORKING BREAK</b>                                                                                                                                                                                   |               |                                                                                                                      |
| <b>13:15 – 16:00 h</b> | <b>Session 2: New Developments in Cancer Therapy</b><br><b>Chair (Hematologist): Bjørn Gjertsen, Haukeland Universitetssykehus, Bergen</b><br><b>Chair (Oncologist): Erik Wist, Ullevål Universitetssykehus, Oslo</b> |               |                                                                                                                      |
| 13:20 – 13:50 h        | <b>Keynote:</b><br><b>“Exploring therapy resistance in vivo – a conceptual syllabus”</b>                                                                                                                              |               | Per Eystein Lønning,<br>Haukeland Universitetssykehus, Bergen                                                        |
| 13:55 – 14:35 h        | <b>Targeted Therapy</b>                                                                                                                                                                                               |               |                                                                                                                      |
|                        | “From cancer specific targets to molecular targeted treatment – evolving paradigms”<br>– A dialogue between the scientist and the clinician                                                                           |               |                                                                                                                      |
|                        | The scientist:                                                                                                                                                                                                        |               | Richard Engh,<br>Universitetet i Tromsø                                                                              |
|                        | The clinician:                                                                                                                                                                                                        |               | Franz Gruber,<br>Sentralsykehuset i Akershus, Oslo                                                                   |
| 14:40 – 15:20 h        | <b>Immunotherapy</b>                                                                                                                                                                                                  |               |                                                                                                                      |
|                        | The scientist:                                                                                                                                                                                                        |               | Gustav Gaudernack,<br>Radiumhospitalet, Oslo                                                                         |
|                        | The clinician:                                                                                                                                                                                                        |               | Steinar Aamdal,<br>Radiumhospitalet, Oslo                                                                            |
| 15:25 – 15:50 h        | “Role of cytotoxics in the new era of targeted therapy<br>– from a scientific to a clinical perspective”                                                                                                              |               | Bo I. Nilsson, Clavis Pharma                                                                                         |
| 15:50 – 16:00 h        | <b>Discussion</b>                                                                                                                                                                                                     |               |                                                                                                                      |
| 16:00 – 16:20 h        | <b>COFFEE BREAK</b>                                                                                                                                                                                                   |               |                                                                                                                      |



## Program

### 1<sup>st</sup> Cancer Crosslinks meeting

at Rikshospitalet in Oslo – January 15, 2009

| Session                | Topic                                                                                                                                                                                                            | Presentations | Presenter                                                 |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------------------------------------------------------|
| <b>16:20 – 18:30 h</b> | <b>Session 3: Challenges for the next decade</b><br>Chair (Hematologist): Per Morten Sandset, Ullevål Universitetssykehus, Oslo<br>Chair (Oncologist): Nils Wilking, Karolinska Universitetssjukhuset, Stockholm |               |                                                           |
| 16:25 – 16:45 h        | “Personalised Medicine”                                                                                                                                                                                          |               | Kjetil Tasken, Bioteknologisenteret, Universitetet i Oslo |
| 16:55 – 17:15 h        | “Long term cancer survivorship – living long with long term effects of therapy”                                                                                                                                  |               | Sophie Fosså, Radiumhospitalet, Oslo                      |
| <b>17:20 – 18:25 h</b> | <b>Clinical Trials: Norway in an international perspective</b>                                                                                                                                                   |               |                                                           |
| 17:20 – 17:45 h        | “Modern therapy: A challenge from a medical, clinical research and economic perspective”<br>“Clinical trials: Lessons learned”                                                                                   |               | Nils Wilking, Karolinska Universitetssjukhuset, Stockholm |
| <b>17:45 – 18:25 h</b> | <b>Roundtable: Why should clinical trials be prioritised?</b>                                                                                                                                                    |               |                                                           |
|                        | Steinar Aamdal, Radiumhospitalet, Oslo                                                                                                                                                                           |               |                                                           |
|                        | Henrik Hjorth-Hansen, St. Olavs Hospital, Trondheim                                                                                                                                                              |               |                                                           |
|                        | Per Eystein Lønning, Haukeland Universitetssykehus, Bergen                                                                                                                                                       |               |                                                           |
|                        | Geir Tjønnfjord, Radiumhospitalet, Oslo                                                                                                                                                                          |               |                                                           |
|                        | <b>Discussion</b>                                                                                                                                                                                                |               |                                                           |
| 18:25 – 18:30 h        | Closing remarks                                                                                                                                                                                                  |               | Bjarte Reve, Oslo Cancer Cluster                          |
| 18:30 h                | TAPAS & WINE                                                                                                                                                                                                     |               |                                                           |